Epigenetic Screening Target insurers, employers, and research organizations with Behavioral Diagnostics' epigenetic screening tools for objective assessment of smoking and alcohol exposure, enabling more accurate underwriting, risk assessment, and compliance in legal cases.

Clinical Trial Partnerships Leverage the July 2026 Versiti collaboration to position BD Holdings as a provider of cancer risk and exposure screening assays for clinical trials, expanding adoption across sponsor sites, CROs, and trial networks.

Expansion Readiness Highlight scalable, cloud-based tech stack and white-label capabilities to potential partners seeking rapid deployment, integration with existing systems (AWS, WordPress, iCIMS), and data privacy compliance for health-related diagnostics.

Revenue Growth Current revenue bracket of 1M-10M and lean team presents an opportunity to upsell mid-market insurers, large employer groups, and specialty clinics with expanded assay panels, ongoing monitoring, and managed services.

Competitive Position Position as a nimble, specialized vendor in behavioral epigenetics with strong use cases in underwriting, employment screening, and litigation support, differentiating from larger, less focused competitors.